Skip to content
Menu

Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL

Benzinga Newsdesk 11 hours ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

– TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels ≥880 mg/dL (≥10

– TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –

– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels ≥880 mg/dL (≥10 mmol/L) and at high risk of developing acute pancreatitis –

Read at benzinga.com